Gain insights regarding disease progression by using Roche NT-proBNP to monitor heart failure patients.
The trend in NT-proBNP levels in heart failure (HF) patients over time gives valuable prognostic information.1,2 The use of Roche NT-proBNP test to monitor patients helps to:
- Identify patients that appear to be doing well symptomatically, yet whose underlying disease is still not in contol3
- Avoid prescribing inertia and ensure your patients' treatment is effective4
Make the right choice in biomarker at every stage of care with Roche NT-proBNP.
In the era of angiotensin receptor-neprilysin inhibitor (ARNi) therapy, the choice in biomarker for HF patients becomes increasingly important. Active B-type natriuretic peptide (BNP) is a neprilysin substrate, making BNP an unsuitable biomarker in HF patients treated with sacubitril-valsartan.4-9 The use of Roche NT-proBNP can help support your clinical decisions to provide the best patient care - especially when a patient's medication regimen is unknown at the time of presenting.